Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to distinguish new and emerging CAR T-cell therapies available for the treatment of relapsed/refractory multiple myeloma (R/R MM) based on safety and efficacy data and line of therapy
Upon completion of this activity, participants should be better able to apply the latest guidelines and clinical evidence to guide the treatment and management of patients with R/R MM with CAR T-cell therapy based on individual patient- and disease-specific factors
Upon completion of this activity, participants should be better able to integrate clinical solutions into practice to improve patient identification, referral, bridging therapy, and adverse event management to enhance CAR T-cell utilization in earlier treatment lines for patients with R/R MM